Patients receiving subcutaneous daratumumab have less chair time and premedication than those receiving IV formulation, says ...

Panelists discuss how patient portal use improves communication by allowing patients to report adverse effects with photos ...

Panelists discuss how patients newly diagnosed with multiple myeloma often face emotional and informational overload, but ...

A quality-adjusted time without symptoms or toxicity analysis identified better outcomes for patients with RCC treated with belzutifan vs everolimus.

Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the ...

Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.

Panelists discuss the evolving role of bispecific antibodies in relapsed/refractory multiple myeloma, emphasizing their value ...

Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell ...

If patients with breast cancer have hyperglycemia or symptoms of it at home, a short break from capivasertib may be required, ...

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of ...

Panelists discuss how the COCOON study’s advanced dermatologic prophylaxis protocol, including systemic antibiotics and ...

Panelists discuss how managing amivantamab-related adverse events such as leg edema requires understanding of underlying ...